Alkermes plc (ALKS)
$
28.85
+0.74 (2.56%)
Key metrics
Financial statements
Free cash flow per share
2.9089
Market cap
4.8 Billion
Price to sales ratio
3.1638
Debt to equity
0.0447
Current ratio
3.2320
Income quality
1.4952
Average inventory
187.7 Million
ROE
0.2365
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alkermes plc, a biopharmaceutical company founded in 1987 and headquartered in Dublin, Ireland, focuses on researching, developing, and commercializing pharmaceutical products to meet the unmet medical needs of patients in various therapeutic areas. The company has a strong market presence, reporting substantial revenue of $1,557,632,000.00 which underscores its operational success. The EBITDA ratio stands at 0.32 highlighting the company's operational efficiency. Furthermore, the earnings per share (EPS) is reported at $2.22 indicating profitability on a per-share basis. Alkermes also earned an interest income of $42,450,000.00 showcasing its ability to generate returns from financial investments. Additionally, the net total of other income and expenses is reported at $23,114,000.00 reflecting the impact of non-core financial activities on the overall financial standing of the company. Among its marketed products are ARISTADA, VIVITROL, and VUMERITY, which address critical psychiatric and neurological conditions, emphasizing the company’s commitment to addressing diverse health challenges. Positioned as a key player in the Biotechnology industry, Alkermes contributes significantly to the overall market landscape while belonging to the Healthcare sector, driving innovation and growth. The stock is affordable at $29.69 making it suitable for budget-conscious investors. With a mid-range market capitalization of $4,762,500,300.00 the company is considered a steady performer in the market. Furthermore, the stock has a high average trading volume of 1,823,464.00 indicating strong liquidity and investor interest. Alkermes demonstrates a robust portfolio that includes not only marketed products but also promising drug candidates in development, such as LYBALVI and nemvaleukin alfa, which aim to further expand the treatment options available to patients.
Is Alkermes plc (ALKS) a good investment?
Investing in Alkermes plc (ALKS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is Alkermes plc (ALKS)'s stock forecast?
Analysts predict Alkermes plc stock to fluctuate between $25.56 (low) and $36.45 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alkermes plc's market capitalization?
As of 2025-08-20, Alkermes plc's market cap is $4,762,500,300, based on 165,078,000 outstanding shares.
How does Alkermes plc compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Alkermes plc has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alkermes plc (ALKS) stock?
To buy Alkermes plc (ALKS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALKS. Place an order (Market, Limit, etc.).
What is the best time to invest in Alkermes plc?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Alkermes plc stock ever split?
Alkermes plc's last stock split was 2:1 on 2000-05-15.
How did Alkermes plc perform in the last earnings report?
Revenue: $1,557,632,000 | EPS: $2.22 | Growth: 3.74%.
Where can I find Alkermes plc's investor relations reports?
Visit https://www.alkermes.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alkermes plc?
You can explore historical data from here
What is the all-time high and low for Alkermes plc stock?
All-time high: $36.45 (2025-02-18) | All-time low: $21.24 (2021-12-01).
What are the key trends affecting Alkermes plc stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with progress around revenue growth from its product portfolio and some pipeline progress. Analyst commentary is positive, and Alkermes has a rock-solid balance sheet with over $1 billion in net cash and no long-term debt.
zacks.com
ALKS beats second-quarter estimates as proprietary product sales rise 14% y/y, offsetting weaker manufacturing and royalty revenues.
seekingalpha.com
Alkermes plc (NASDAQ:ALKS ) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.
zacks.com
Alkermes (ALKS) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.72 per share a year ago.
zacks.com
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
investors.com
Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.
prnewswire.com
– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Detailed Results to Be Presented at Upcoming World Sleep Congress – – Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy – DUBLIN , July 21, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly referred to as ALKS 2680, is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment for NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).
zacks.com
The consensus price target hints at a 33.2% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
See all news
